SCHEMBL16667889

SCHEMBL16667889

N#Cc1ccc(N(C(=O)O)c2ccccc2)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
NPC1 O15118 1/20 0.43
CCNK O75909 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
CDK12 Q9NYV4 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PTGIR P43119 3/20 0.37
ALDH1A1 P00352 1/20 0.36
NTRK1 P04629 1/20 0.36
NTRK3 Q16288 1/20 0.36
NTRK2 Q16620 1/20 0.36
JAK2 O60674 1/20 0.36
SNCA P37840 1/20 0.36
ATR Q13535 2/20 0.36
FFAR1 O14842 1/20 0.35
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
SCN9A Q15858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14698064 0.79 KMT2A (0.54) KMT2AMEN1NPC1NPSR1ALDH1A1
SCHEMBL19714338 0.76 PTGIR (0.52) KMT2ANPC1NPSR1PTGIRALDH1A1
SCHEMBL16167096 0.76 ALDH1A1 (0.46) KMT2AMEN1NPC1NPSR1PTGIR
SCHEMBL57851 0.76 TRPM8 (0.43) KMT2AMEN1NPC1NPSR1PTGIR
SCHEMBL3840073 0.73 MEN1 (0.42) KMT2AMEN1NPC1NPSR1ALDH1A1
SCHEMBL14300714 0.73 PTGIR (0.55) KMT2ANPC1NPSR1PTGIRALDH1A1
SCHEMBL16667853 0.72 STK4 (0.39) KMT2ANPSR1ALDH1A1CRHBPCRHR2
SCHEMBL1081803 0.72 NPSR1 (0.41) KMT2AMEN1NPC1NPSR1PTGIR
SCHEMBL10855054 0.72 NPSR1 (0.50) KMT2AMEN1NPC1NPSR1PTGIR
SCHEMBL14697483 0.71 KCNA5 (0.46) KMT2AMEN1NPC1NPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9266883-B2 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2016-02-23 US disclosed
US-20150119385-A1 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors NOVARTIS AG (CH) 2015-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119385-A1 Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors FGFR4, FGFR1, FGFR3 KMT2A 1316/4885MEN1 2918/4885NPC1 2100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.